Article Text
Statistics from Altmetric.com
Optimal treatment for patients with relapsing lupus nephritis remains unclear. The ability of 15-deoxyspergualin (gusperimus; 15-DSG) to suppress systemic lupus erythematosus (SLE)-like diseases has been demonstrated in animals and humans.1–4 15-DSG exerted no nephrotoxicity or hepatotoxicity but reversibly induced leucocytopenia.5,6
In this study we aimed at evaluating the safety of 15-DSG in the treatment of glomerulonephritis associated with SLE.
CASE REPORTS
Table 1 shows the patient characteristics.
- In this window
- In a new window
15-DSG was provided by Nippon Kayaku Co Ltd, Tokyo, Japan. Patients gave their informed consent, and 15-DSG 0.5 mg/kg normal body weight (height in cm minus 100)/day was self administered subcutaneously for 14 days, followed by a break of 7 days ( = 1 cycle). The dose was adjusted (dependent on efficacy or safety, or both) after cycles 4 and 6 to 0.35 mg/kg and 0.25 mg/kg, or 0.7 mg/kg and 1.0 mg/kg.
Patient 1
After a bolus, daily …
Footnotes
-
PAH is an employee of Euro Nippon Kayaku, a branch of the mother company Nippon Kayaku, Tokyo, Japan, which provided the drug for this trial free of charge.
Treatment of SLE-GN with 15-DSG was approved by the local ethics committee.